Tag: chronic venous insufficiency
I-Vasc announces €1.8 million Series A investment to launch its Velex...
I-Vasc, developer of the Velex device with its empty vein ablation (EVA) technology for the treatment of chronic venous insufficiency (CVI), has announced the...
AVF 2022: Emerging autogenous venous valve formation system sees “continual improvement”
An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...
AVF 2022: VenoValve improvement “maintained” for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum...
Vesper Medical announces completion of enrolment in the VIVID trial
Vesper Medical recently announced the completion of enrolment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper...
InterVene’s BlueLeaf endovenous valve formation system granted FDA Breakthrough Device designation
InterVene recently announced that it has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for the company’s BlueLeaf endovenous valve...
BD acquires Venclose to extend chronic venous disease treatment portfolio
BD announced today it has acquired Venclose, a provider of solutions for the treatment of chronic venous insufficiency (CVI).
"We are committed to setting a...
Envveno Medical reports successful completion of first VenoValve surgery for US...
Envveno Medical, formerly Hancock Jaffe Laboratories, recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has...
Hancock Jaffe presents positive two-year VenoValve data at SVS VAM 2021
Hancock Jaffe Laboratories has announced that promising two-year post-VenoValve implantation data are being presented today at the Society for Vascular Surgery’s Vascular Annual Meeting...
FDA grants Breakthrough Device designation status for Hancock Jaffe’s VenoValve
Hancock Jaffe Laboratories today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation status to the VenoValve, the company’s...
Hancock Jaffe, maker of the VenoValve, completes US$41 million public offering
Hancock Jaffe Laboratories recently announced that it has completed a public offering of its securities, generating approximately US$41.4 million of gross proceeds, prior to...
RCT finds addition of aquatic activity to chronic venous insufficiency treatment...
Results of the ATLANTIS (Aquatic therapy to lower adverse consequences of venous thrombosis and insufficiency) randomised controlled trial (RCT) show that the addition of...
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system (Medtronic) is “a promising therapeutic option for anatomic success at six months”. This study, published in...
Chronic venous insufficiency identified as a leading cause of lower extremity...
A retrospective analysis of patients diagnosed with lower extremity lymphoedema, and treated in a cancer-affiliated physical therapy department, has found that chronic venous insufficiency...
Initial results from first-in-man trial of prosthetic VenoValve demonstrate promise
Initial results of an ongoing first-in-man study in Colombia, that saw the implantation of a prosthetic venous valve in 15 patients, have demonstrated an...
Patients treated for pathologic perforator veins should be evaluated for multilevel...
Findings of a recent study on whether a pathologic perforator can predict the presence of an ipsilateral central venous stenosis, as presented at the...
US study finds racial disparities in outcomes of superficial vein treatments
A US-based multicentre study has found that while chronic venous insufficiency is “primarily observed in white women”, there are other notable differences in the...
InterVene Raises $15 Million in Series B funding for catheter-based deep...
InterVene has announced it has raised US$15 million in a Series B financing round. The company’s BlueLeaf Endovenous Valve Formation System is the first catheter-based solution...
Medical research committee gives approval for first-in-man VenoValve study
Hancock Jaffe Laboratories, a company specialising in bioprosthetic medical devices for treating cardiac and vascular diseases, has received approval for the first-in-man testing of...
A novel compression solution for chronic venous insufficiency
Compression therapy is the mainstay of treatment for the symptoms of chronic venous insufficiency (CVI). CVI is treated with compression stockings or multilayer bandaging....